Key terms
About PDSB
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PDSB news
Today
8:25am ET
Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)
Today
7:25am ET
PDS Biotechnology: Strategic Shift to Triplet Therapy Promises Enhanced Clinical Success
Yesterday
7:36am ET
PDS Biotechnology reports 2023 EPS ($1.39), consensus ($1.46)
Yesterday
7:34am ET
PDS Biotechnology to prioritize triple combination in place of VERSATILE-003
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 13
8:23am ET
PDS Biotechnology announces publication of research, patent grant
Jan 22
4:48pm ET
PDS Biotechnology CMO Lauren Wood retires, Kirk Shepard succeeds
No recent news articles are available for PDSB
No recent press releases are available for PDSB
PDSB Financials
Key terms
Ad Feedback
PDSB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PDSB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range